Curie Brief
Turn on cookies to sign in
Signing in saves your progress to your Curie account. We can only do that with cookies on — turn them on to continue.
NewsThe FDA has approved Brytly, a new over-the-counter eye drop designed to relieve eye redness from minor irritations. Made by Alcon, the apraclonidine-based solution is cleared for use in people aged 12 and older, up to twice daily. The approval reflects the FDA's push to expand access to affordable, convenient nonprescription treatments.
The FDA has approved Brytly (apraclonidine ophthalmic solution, 0.125%) — a new nonprescription eye drop from Alcon — for the relief of eye redness caused by minor irritations. Available without a prescription, Brytly gives consumers a convenient option to manage redness without a trip to the doctor's office.
The approval aligns with the FDA's broader commitment to increasing access to affordable medicines. FDA Center for Drug Evaluation and Research director Mike Davis, MD, PhD, noted that expanding nonprescription treatment options is a key agency priority.
Quick Facts:
Why it matters: With Brytly now available without a prescription, patients have a new, accessible tool for managing everyday eye redness — no appointment required. For eye care providers, it's worth flagging the contact lens and multi-drop timing guidance to share with patients who may self-manage with this product.
